Advertisement

Drugs

, Volume 55, Issue 1, pp 5–30 | Cite as

The Taxoids

Comparative Clinical Pharmacology and Therapeutic Potential
  • Elizabeth A. EisenhauerEmail author
  • Jan B. Vermorken
Review Article

Summary

Paclitaxel and docetaxel are 2 compounds from the new taxoid class of anti-cancer agents. Both drugs are very similar in preclinical activity, mechanism of action and spectrum of clinical activity. Some subtle differences in the intracellular retention of docetaxel may account for its lack of schedule-related myelosuppression and greater potency, and may be relevant to the skin toxicity and oedema which it produces. Early data suggest that there may be differing behaviour of anthracycline/taxoid combinations with respect to cardiotoxicity.

Paclitaxel has been studied in several first-line combination therapy trials in ovarian cancer. Here, paclitaxel in combination with a platinum compound seems to have proven itself as a standard regimen. It is uncertain if docetaxel will be evaluated in this context.

An abundance of clinical data is available for both analogues in the advanced, metastatic setting of breast cancer. Both also have been compared as single agents with doxorubicin with the results suggesting paclitaxel in a 3-hour infusion is inferior to the anthracycline (in terms of response rate), and those of docetaxel suggesting it is superior to the same dose of doxorubicin. This indirect comparison favours the activity of docetaxel; however, it is clear that in the dose/schedules studied, the taxoid compounds are not equitoxic. Either agent by itself, in the treatment of metastatic breast cancer, remains appropriate; however, lack of cumulative toxicity may make paclitaxel more attractive in some situations where prolonged administration is foreseen.

Lung cancer trials have also confirmed the activity of both agents, although docetaxel appears to have slightly more promising activity in previously treated patients than paclitaxel. Paclitaxel in combination with cisplatin has been evaluated in randomised trials as first-line treatment of non-small-cell lung cancer (NSCLC). The results of these trials taken together suggest that this combination has an impact on survival similar to other new regimens now considered ‘standard’ in the front-line setting in this disease.

Unfortunately, despite all the phase II data generated in numerous tumour types, little else can be said about the role of either taxoid in the ‘standard’ management of malignant disease. It will be some years yet before taxoid-based combinations have been evaluated sufficiently in randomised trials such that the impact of this novel class can be adequately assessed in terms of survival and cure rates.

Keywords

Paclitaxel Doxorubicin Docetaxel Adis International Limited Clin Oncol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wani MC, Taylor HL, Wall ME, et al. Plant antitumour agents. VI: The isolation and structure of taxol: a novel antileukemic and antitumour agents from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325–7PubMedCrossRefGoogle Scholar
  2. 2.
    Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665–7PubMedCrossRefGoogle Scholar
  3. 3.
    Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288–91PubMedCrossRefGoogle Scholar
  4. 4.
    Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747–55PubMedCrossRefGoogle Scholar
  5. 5.
    Andreu JM, Diaz JF, Gil R, et al. Solution structure of Taxotere-induced microtubules to 3-nm resolution: the change in protofilament number is linked to the binding of the taxol side chain. J Biol Chem 1994; 269: 31785–92PubMedGoogle Scholar
  6. 6.
    Riou JF, Petitgenet O, Combeau C, et al. Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line [abstract]. Proc Am Assoc Cancer Res 1994; 35: 385Google Scholar
  7. 7.
    Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995; 22 Suppl. 4: 3–16Google Scholar
  8. 8.
    Rose WC. Taxol: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs 1992; 3: 311–21PubMedCrossRefGoogle Scholar
  9. 9.
    Donehower RC, Rowinsky EK, Grochow LB, et al. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987; 71: 1171–7PubMedGoogle Scholar
  10. 10.
    Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995; 13: 1609–4PubMedGoogle Scholar
  11. 11.
    Kris MG, O’Connel JP, Gralla R, et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986; 70: 605–7PubMedGoogle Scholar
  12. 12.
    Brown T, Havlin K, Weiss G, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9: 1261–7PubMedGoogle Scholar
  13. 13.
    Wiernik PH, Schwartz EL, Straumann JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486–93PubMedGoogle Scholar
  14. 14.
    Ohnuma T, Zimet AS, Coffey VA, et al. Phase I study of taxol in a 24-hour infusion schedule [abstract]. Proc Am Assoc Cancer Res 1985; 26: 662Google Scholar
  15. 15.
    Wiernik PH, Schwartz EL, Einzig A, et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232–9PubMedGoogle Scholar
  16. 16.
    Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165–70PubMedGoogle Scholar
  17. 17.
    Spriggs DR, Tondini C. Taxol administered as a 120 hour infusion. Invest New Drugs 1992; 10: 275–8PubMedCrossRefGoogle Scholar
  18. 18.
    Legha SS, Tenny DM, Krakow IR. Phase I study of taxol using a 5-day intermittent schedule. J Clin Oncol 1986; 4: 762–6PubMedGoogle Scholar
  19. 19.
    Grem JL, Tutsch KD, Simon KJ, et al. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 1987; 71: 1179–84PubMedGoogle Scholar
  20. 20.
    Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621–9PubMedGoogle Scholar
  21. 21.
    Eisenhauer EA, ten Bokkel-Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654–66PubMedGoogle Scholar
  22. 22.
    Tange UB, Lund B, Hansen HH, et al. Phase I study of Taxotere (docetaxel) in patients (pts) with solid tumors [abstract]. Proc Am Soc Clin Oncol 1994; 13: 406Google Scholar
  23. 23.
    Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53: 1037–42PubMedGoogle Scholar
  24. 24.
    Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as an intravenous 1-hour infusion on a weekly basis. J Clin Oncol 1994; 12: 1458–67PubMedGoogle Scholar
  25. 25.
    Burris HA, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour infusion. J Clin Oncol 1993; 11: 950–8PubMedGoogle Scholar
  26. 26.
    Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere, five day schedule. J Natl Cancer Inst 1992; 84: 1781–8PubMedCrossRefGoogle Scholar
  27. 27.
    Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion. Cancer Res 1993; 53: 523–7PubMedGoogle Scholar
  28. 28.
    Piccart MJ, Klijn J, Paridaens R, et al. Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: final results of a randomized trial of the EORTC Investigational Drug Branch for Breast Cancer (IDBBC) [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S75CrossRefGoogle Scholar
  29. 29.
    Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688–99PubMedGoogle Scholar
  30. 30.
    Postma TJ, Vermorken JB, Liefting AJM, et al. Paclitaxel induced neuropathy. Ann Oncol 1995; 6: 489–94PubMedGoogle Scholar
  31. 31.
    Hilkens PH, Verweij J, Stoter G, et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104–8PubMedCrossRefGoogle Scholar
  32. 32.
    Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004–14PubMedCrossRefGoogle Scholar
  33. 33.
    Huizing MT, Sewberath Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13: 381–404PubMedCrossRefGoogle Scholar
  34. 34.
    Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J Clin Oncol 1993; 11: 2127–35PubMedGoogle Scholar
  35. 35.
    Sonnichsen DS, Hurwitz CA, Pratt CB, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994; 12: 532–8PubMedGoogle Scholar
  36. 36.
    Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180–90PubMedGoogle Scholar
  37. 37.
    Longnecker S, Ross D, Grochow L. High performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987; 71: 53–9PubMedGoogle Scholar
  38. 38.
    Lustig V, Rosing H, van Warmerdam LJC, et al. Limited sampling models for the pharmacokinetics of docetaxel. Clin Drug Treat 1997; 13: 247–54Google Scholar
  39. 39.
    Huizing MT, van Warmerdam LJC, Rosing H, et al. Limited sampling strategies for investigating paclitaxel pharmacokinetics in patients receiving 175 mg/m2 as a 3-hour infusion. Clin Drug Invest 1995; 9: 344–53CrossRefGoogle Scholar
  40. 40.
    Bruno R, Vivien N, Vergniol JC, et al. A population pharmacokinetics model for docetaxel (Taxotere®): model building and validation. J Pharmacokinet Biopharm 1996; 2: 153–73Google Scholar
  41. 41.
    Walle T, Walle UK, Kumar GN, et al. Taxol metabolism and disposition in cancer patients. Drug Metab Disp 1995; 23: 506–12Google Scholar
  42. 42.
    Aapro MS, Zulian G, Alberto P, et al. Phase I and pharmacokinetic study of RP56976 in a new ethanol-free formulation of Taxotere [abstract]. Ann Oncol 1992; 3 Suppl. 5: 53Google Scholar
  43. 43.
    Paccaly D, Sanderink G, Paccaly-Moulin A, et al. Docetaxel (RP 56976, Taxotere®) human pharmacokinetics: technical summary. Rhone-Poulenc Rorer, 1994 Jul. (Data on file)Google Scholar
  44. 44.
    Huizing MT, Giaccone G, van Warmerdan LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and dose sequencing study in patients with non-small cell lung cancer. J Clin Oncol 1997; 15: 317–29PubMedGoogle Scholar
  45. 45.
    Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Center (ECC) trial. Ann Oncol 1995; 6: 699–704PubMedGoogle Scholar
  46. 46.
    Nannan Panday VR, Huizing MT, Willemse PHB, et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 1997; 24 Suppl. 11: S11–34–38Google Scholar
  47. 47.
    Venook AP, Egorin M, Brown JD, et al. Paclitaxel (Taxol) in patients with liver dysfunction (CALGB 9264) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 139Google Scholar
  48. 48.
    Huizing MT, Rosing H, Vermorken JB, et al. Pharmacology of paclitaxel (P) and metabolites in patients with altered liver function [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S192CrossRefGoogle Scholar
  49. 49.
    Bruno R, Hille D, Thomas L, et al. Population pharmacokinetics/pharmacodynamics of docetaxel (Taxotere®) [abstract]. Proc Am Soc Clin Oncol 1995; 14: 457Google Scholar
  50. 50.
    Fulton B, Spencer CM. Docetaxel: a review of the pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996 Jun; 51(6): 1075–92PubMedCrossRefGoogle Scholar
  51. 51.
    Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1691–703Google Scholar
  52. 52.
    Kennedy MJ, Zahurak ML, Donehower RC, et al. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony stimulating factor in women with previously untreated breast cancer. J Clin Oncol 1996; 14: 783–91PubMedGoogle Scholar
  53. 53.
    Holmes FA, Valero V, Walters RS, et al. The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Monogr Natl Cancer Inst 1993; 15: 161–9PubMedGoogle Scholar
  54. 54.
    Sledge Jr GW. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience. Semin Oncol 1995; 22: 123–5PubMedGoogle Scholar
  55. 55.
    Holmes FA, Newman EA, Madden T, et al. Schedule dependent pharmacokinetics in a phase I trial of taxol and doxorubicin as initial chemotherapy for metastatic breast cancer [abstract]. Ann Oncol 1994; 5: 191Google Scholar
  56. 56.
    Gianni L, Vigano L, Locarelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906–15PubMedGoogle Scholar
  57. 57.
    Pronk LC, Schellens JHM, Planting AST, et al. Phase I and pharmacokinetic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15: 1071–9PubMedGoogle Scholar
  58. 58.
    Schellens JHM, Ma J, Bruno R, et al. Pharmacokinetics of cisplatin and Taxotere® (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence Taxotere®/cisplatin and cisplatin/Taxotere® in a phase I/II study in solid tumor patients [abstract]. Proc Am Soc Clin Oncol 1994; 13: 132Google Scholar
  59. 59.
    Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797–805PubMedCrossRefGoogle Scholar
  60. 60.
    Reichman BS, Seidman AD, Crown JPA, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943–51PubMedGoogle Scholar
  61. 61.
    Swain SM, Honig SF, Tefft MC, et al. A phase II trial of paclitaxel (Taxol®) as first-line treatment in advanced breast cancer. Invest New Drugs 1995; 13: 217–2PubMedCrossRefGoogle Scholar
  62. 62.
    Davidson NG, Perren TJ, Chao YTS, et al. A phase II non-randomized study of paclitaxel (P) 225 mg/m2 over 3 hours q 21 days in patients (pts) failing initial therapy for breast cancer [abstract]. Proceedings of the Sixth International Congress on Anti-Cancer Treatment 1995; 5: 119Google Scholar
  63. 63.
    Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87: 1169–75PubMedCrossRefGoogle Scholar
  64. 64.
    Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575–81PubMedGoogle Scholar
  65. 65.
    Fountzilas G, Athanassiades A, Giannakakis T, et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996; 32A: 47–51PubMedCrossRefGoogle Scholar
  66. 66.
    Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858–67PubMedGoogle Scholar
  67. 67.
    Peretz T, Sulkes A, Chollet P, et al. A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC) [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S75CrossRefGoogle Scholar
  68. 68.
    Seidman AD, Reichman BS, Crown JPA, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152–9PubMedGoogle Scholar
  69. 69.
    Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14: 1877–84PubMedGoogle Scholar
  70. 70.
    Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J Clin Oncol 1995; 13: 2056–65PubMedGoogle Scholar
  71. 71.
    Hudis CA, Seidman AD, Crown JPA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 58–65PubMedGoogle Scholar
  72. 72.
    Trudeau ME, Eisenhauer EA, Higgins BP Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 422–8PubMedGoogle Scholar
  73. 73.
    Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314–22PubMedGoogle Scholar
  74. 74.
    Dieras V, Fumoleau P, Chevallier B et al. Second EORTC-Clinical Screening Group (CSG) phase II trial of Taxotere® (docetaxel) as first-line chemotherapy (CT) in advanced breast cancer (ABC) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 78Google Scholar
  75. 75.
    Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the safety and efficacy of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996; 7: 165–71PubMedCrossRefGoogle Scholar
  76. 76.
    ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 527–32PubMedGoogle Scholar
  77. 77.
    Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996; 73: 210–6PubMedCrossRefGoogle Scholar
  78. 78.
    Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel (Taxotere®): a highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886–94PubMedGoogle Scholar
  79. 79.
    Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879–85PubMedGoogle Scholar
  80. 80.
    Guastalla JP, Bonneterre J, Fumoleau P, et al. A phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S75CrossRefGoogle Scholar
  81. 81.
    Paridaens R, Bruning P, Klijn J, et al. An EORTC crossover trial comparing Taxol (T) and doxorubicin (D) as first- and second-line chemotherapy (CT) in advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 154aGoogle Scholar
  82. 82.
    Chan S, Friedrichs K, Noel D, et al. A randomized phase III study of Taxotere (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen: preliminary results [abstract]. Proc Am Soc Clin Oncol 1997; 16: 154aGoogle Scholar
  83. 83.
    Fisherman JS, Cowan KH, Noone M, et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte-colony stimulating factor in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 774–82PubMedGoogle Scholar
  84. 84.
    Gelmon KA, O’Reilly SE, Tolcher AW, et al. Phase I/II trial of bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996; 14: 1185–91PubMedGoogle Scholar
  85. 85.
    Gehl J, Boesgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7: 687–93PubMedCrossRefGoogle Scholar
  86. 86.
    Conte PF, Baldini E, Gennari A, et al. Dose-finding study and phannacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997; 15: 2510–7PubMedGoogle Scholar
  87. 87.
    Bourgeois H, Gruia G, Dieras V, et al. Docetaxel in combination with doxorubicin as first-line chemotherapy of metastatic breast cancer: a phase I dose-finding study [abstract]. Proc Am Soc Clin Oncol 1996; 15: 148Google Scholar
  88. 88.
    Sledge Jr GW, Neuberg D, Ingle J, et al. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial [abstract]. Proc Am Soc Clin Oncol 1997; 16: 1aGoogle Scholar
  89. 89.
    Bishop JF, Dewar J, Tattersall MHN, et al. Taxol® (paclitaxel) alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 153aGoogle Scholar
  90. 90.
    McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–9PubMedGoogle Scholar
  91. 91.
    Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748–53PubMedGoogle Scholar
  92. 92.
    Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive for ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 1994; 12: 1748–53PubMedGoogle Scholar
  93. 93.
    Seewaldt VL, Greer BE, Cain JM, et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol 1994; 170: 1666–70PubMedGoogle Scholar
  94. 94.
    Gore ME, Levy V, Rustin G, et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72: 1016–9PubMedCrossRefGoogle Scholar
  95. 95.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6PubMedCrossRefGoogle Scholar
  96. 96.
    Piccart MJ, Bertelsen K, Stuart G, et al. Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca)? The EORTC-GCCG, NOCOVA, NCI-C, and Scottish Intergroup experience [abstract]. Proc Am Soc Clin Oncol 1997; 16: 352aGoogle Scholar
  97. 97.
    Muggia FM, Braly PS, Brady MF, et al. Phase III study of cisplatin (P) or paclitaxel (T) versus their combination in sub-optimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132 [abstract]. Proc Am Soc Clin Oncol 1997; 16: 352aGoogle Scholar
  98. 98.
    Bookman MA, McGuire WP, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895–902PubMedGoogle Scholar
  99. 99.
    Bolis G. Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Semin Oncol 1995; 22 (6 Suppl. 14): 32–4PubMedGoogle Scholar
  100. 100.
    ten Bokkel Huinink W, Veenhof, Heimerhorst T, et al. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol 1995; 22 (3 Suppl. 6): 97–100Google Scholar
  101. 101.
    Giaccone G, Huizing M, ten Bokkel Huinink W, et al. Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers. Semin Oncol 1994; 21 (5 Suppl. 8): 34–8PubMedGoogle Scholar
  102. 102.
    Calvert AH, Boddy A, Bailey NP, et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 1995; 22 (5 Suppl. 12): 91–8PubMedGoogle Scholar
  103. 103.
    Neijt JP, Hansen M, Hansen SW, et al. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin [abstract]. Proc Am Soc Clin Oncol 1997; 16: 352aGoogle Scholar
  104. 104.
    Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995; 13: 2961–7Google Scholar
  105. 105.
    Vermorken JB, Huijskes R, Hoekman K, et al. Feasibility and efficacy of a 2-weekly taxol, epirubicin and cisplatin (TEC) regimen in patients with advanced ovarian cancer (ADOVCA) [abstract]. Proc Am Assoc Cancer Res 1996; 37: 169Google Scholar
  106. 106.
    Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum refractory ovarian cancer. J Clin Oncol 1994; 12: 2301–8PubMedGoogle Scholar
  107. 107.
    Piccart MJ, Gore M, ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87: 676–81PubMedCrossRefGoogle Scholar
  108. 108.
    Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388–94PubMedCrossRefGoogle Scholar
  109. 109.
    Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 384–8PubMedCrossRefGoogle Scholar
  110. 110.
    Gatzmeier U, Heckmayr M, Neuhauss R, et al. Phase II study of paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 1995; 12 Suppl. 2: S101–6CrossRefGoogle Scholar
  111. 111.
    Sekine I, Nishiwaki Y, Watanabe K, et al. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res 1996; 2: 941–5PubMedGoogle Scholar
  112. 112.
    Millward MJ, Bishop JF, Friedlander M, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 1996; 14: 142–8PubMedGoogle Scholar
  113. 113.
    Murphy WK, Winn RJ, Huber M, et al. Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy [abstract]. Proc Am Soc Clin Oncol 1994; 13: 363Google Scholar
  114. 114.
    Ruckdeschel J, Wagner Jr H, Williams C, et al. Second-line chemotherapy for resistant, metastatic, non-small cell lung cancer (NSCLC): the role of Taxol [abstract]. Proc Am Soc Clin Oncol 1994; 13: 357Google Scholar
  115. 115.
    Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994; 12: 1238–44PubMedGoogle Scholar
  116. 116.
    Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994; 12: 1232–7PubMedGoogle Scholar
  117. 117.
    Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere®) is active in non-small cell lung cancer: a phase II study of the EORTC early clinical trials group (ECTG). Br J Cancer 1994; 70: 384–7PubMedCrossRefGoogle Scholar
  118. 118.
    Burris H, Eckardt J, Fields S, et al. Phase II trials of Taxotere in patients with non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12: 335Google Scholar
  119. 119.
    Miller VA, Rigas JR, Francis PA, et al. Phase II trial of 75 mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995; 75: 968–72PubMedCrossRefGoogle Scholar
  120. 120.
    Kunitoh H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: a Japanese cooperative group study. J Clin Oncol 1996; 14: 1649–55PubMedGoogle Scholar
  121. 121.
    Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995; 13: 645–51PubMedGoogle Scholar
  122. 122.
    Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer (NSCLC): a phase II toxicity, response and survival analysis. J Clin Oncol 1995; 13: 1860–70PubMedGoogle Scholar
  123. 123.
    Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer — a phase II trial. J Clin Oncol 1996; 14: 2054–60PubMedGoogle Scholar
  124. 124.
    Shepherd FA, Latreille J, Crump M, et al, A phase I study of paclitaxel and ifosfamide in advanced non-small cell lung cancer. Ann Oncol 1996; 7: 311–3PubMedCrossRefGoogle Scholar
  125. 125.
    Chang AY, DeVore R, Johnson D. Pilot study of vinorelbine and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 1996; 23 (2 Suppl. 5): 19–21PubMedGoogle Scholar
  126. 126.
    Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol 1994; 12: 2682–6PubMedGoogle Scholar
  127. 127.
    Kirkbride P, Eisenhauer E, Gelmon K, et al. Phase I trial of paclitaxel (Tax) and radical radiotherapy (XRT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 392Google Scholar
  128. 128.
    Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group (ECOG) trial [abstract]. Proc Am Soc Clin Oncol 1996; 15: 382Google Scholar
  129. 129.
    Giaccone G, Postmus P, Debruyne C, et al. Final results of an EORTC phase III study of paclitaxel versus teniposide, in combination with cisplatin, in advanced NSCLC [abstract]. Proc Am Soc Clin Oncol 1997; 16: 460aGoogle Scholar
  130. 130.
    LeChevalier T, Belli L, Monnier A, et al. Phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1995; 14: 350Google Scholar
  131. 131.
    Cole JT, Gralla RJ, Marques CB, et al. Phase I–II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1995; 14: 357Google Scholar
  132. 132.
    Kourousis C, Kakolyris S, Androullakis N, et al. First-line treatment on non-small cell lung carcinoma with docetaxel and vinorelbine: a phase II study [abstract]. Proc Am Soc Clin Oncol 1996; 15: 405Google Scholar
  133. 133.
    Masters GA, Haraf DJ, Hoffman PC, et al. Phase I study of concomitant docetaxel (Taxotere, TXT) and radiation (RT) in advanced chest malignancies [abstract]. Proc Am Soc Clin Oncol 1996; 15: 374Google Scholar
  134. 134.
    Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive-disease small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1995; 13: 1430–5PubMedGoogle Scholar
  135. 135.
    Kirschling RJ, Jung SH, Jett JR. A phase II study of Taxol and G-CSF in previously untreated patients with extensive stage small cell lung cancer (SCC) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 326Google Scholar
  136. 136.
    Smit EF, Kloosterziel C, Groen HJM, et al. A phase II study of paclitaxel (P) in heavily pretreated patients with small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 394Google Scholar
  137. 137.
    Latreille J, Cormier Y, Martins H, et al. Phase II study of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 1996; 13: 343–5PubMedCrossRefGoogle Scholar
  138. 138.
    Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994; 30A: 1058–60PubMedCrossRefGoogle Scholar
  139. 139.
    Forastiere AA. Current and future trials of Taxol (paclitaxel) in head and neck cancer. Ann Oncol 1995; 5 Suppl. 6: S51–4Google Scholar
  140. 140.
    Thornton D, Singh K, Putz B, et al. A phase II trial of taxol in squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1994; 13: 288Google Scholar
  141. 141.
    Gebbia V, Testa A, Cannata G, et al. Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 1996; 32A: 901–2PubMedCrossRefGoogle Scholar
  142. 142.
    Catimel G, Verweij J, Mattijson V, et al. Docetaxel (Taxotere®): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 533–7PubMedGoogle Scholar
  143. 143.
    Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14: 1672–8PubMedGoogle Scholar
  144. 144.
    Couteau C, Leyvraz S, Oulid-Aissa D, et al. A phase II study of docetaxel in squamous cell carcinoma (SCC) of the head and neck [abstract]. Proc Am Soc Clin Oncol 1996; 15: 315Google Scholar
  145. 145.
    Ebihara S, Fujii M, Sasaki Y, et al. A late phase II study of docetaxel (Taxotere®) in patients with head and neck cancer (HNC) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 399aGoogle Scholar
  146. 146.
    Vermorken JB, Catimel G, Stupp R, et al. Randomized phase II trial of methotrexate (MTX) versus two schedules of Taxol (T) in patients with advanced squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1997; 16: 410aGoogle Scholar
  147. 147.
    Fujii H, Sasaki Y, Ebihara S, et al. An early phase II study of docetaxel (Taxotere®) in patients with head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1994; 14: 298Google Scholar
  148. 148.
    Jekunen AP, Christen RD, Shalinsky DR, et al. Synergistic interaction between cisplatin and Taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994; 69: 299–306PubMedCrossRefGoogle Scholar
  149. 149.
    Forastiere AA, Leong T, Murphy B, et al. A phase III trial of high-dose paclitaxel + cisplatin + G-CSF versus low dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): an Eastern Cooperative Oncology Group trial [abstract]. Proc Am Soc Clin Oncol 1997; 16: 384aGoogle Scholar
  150. 150.
    Hitt R, Hornedo J, Colomer R, et al. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Semin Oncol 1995; 22 Suppl. 15: 50–4PubMedGoogle Scholar
  151. 151.
    Schoffski P, Wanders J, Catimel G, et al. Docetaxel and cisplatin: a highly active regimen for squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1996; 15: 310Google Scholar
  152. 152.
    Posner M, Norris C, Colevas A, et al. Phase I/II trial of docetaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) for curable, locally advanced squamous cell cancer of the head and neck (SCCHN) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 387aGoogle Scholar
  153. 153.
    Bruntsch U, Heinrich B, Kaye SB, et al. Docetaxel (Taxotere) in advanced renal cell cancer: a phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A: 1064–7PubMedCrossRefGoogle Scholar
  154. 154.
    Mertens WC, Eisenhauer EA, Jolivet J, et al. Docetaxel in advanced renal carcinoma: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 185–7PubMedGoogle Scholar
  155. 155.
    Pazdur R, Lassere Y, Soh LT, et al. Phase II trial of docetaxel (Taxotere®) in metastatic colorectal cancer. Ann Oncol 1994; 5: 468–70PubMedGoogle Scholar
  156. 156.
    Sternberg CN, ten Bokkel Huinink WW, Smyth JF, et al. Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group study. Br J Cancer 1994; 70: 376–9PubMedCrossRefGoogle Scholar
  157. 157.
    Legha SS, Ring S, Papadopoulos N, et al. A phase II trial of taxol in metastatic melanoma. Cancer 1990; 65: 2478–81PubMedCrossRefGoogle Scholar
  158. 158.
    Einzig A, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9: 59–64PubMedCrossRefGoogle Scholar
  159. 159.
    Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995; 13: 2895–9PubMedGoogle Scholar
  160. 160.
    Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A: 1061–4PubMedCrossRefGoogle Scholar
  161. 161.
    Einzig AI, Schuchter LM, Wadler S, et al. Phase II trial of Taxotere (RP 56976) in patients (pts) with metastatic melanoma previously untreated with cytotoxic chemotherapy [abstract]. Proc Am Soc Clin Oncol 1994; 13: 395Google Scholar
  162. 162.
    McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 1996; 14: 792–5PubMedGoogle Scholar
  163. 163.
    Kudelka AP, Winn R, Edwards CL, et al. Advanced squamous cell cancer (SCC) of the cervix: a multicenter phase II study of paclitaxel (Taxol) 250 mg/m2 administered intravenously (IV) over 3h every 21 days with G-CSF support [abstract]. Proc Am Soc Clin Oncol 1996; 15: 281Google Scholar
  164. 164.
    Kudelka AP, Verschraegen CF, Levy T, et al. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anti Cancer Drugs 1996; 7: 398–401PubMedCrossRefGoogle Scholar
  165. 165.
    Prados MD, Schold SC, Spence AM, et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 1996; 14: 2316–21PubMedGoogle Scholar
  166. 166.
    Chamberlain MC, Kormanink P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 1995; 13: 2066–71PubMedGoogle Scholar
  167. 167.
    Forsyth P, Cairncross G, Stewart D, et al. Phase II trial of docetaxel in patients with recurrent malignant glioma. Invest New Drugs 1996; 14: 203–6PubMedCrossRefGoogle Scholar
  168. 168.
    Glantz MJ, Choy H, Kearns CM, et al. Phase I study of weekly outpatient paclitaxel and concurrent irradiation in adults with astrocytomas. J Clin Oncol 1996; 14: 600–9PubMedGoogle Scholar
  169. 169.
    van Hoesel QGCM, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere™) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994; 5: 539–42PubMedGoogle Scholar
  170. 170.
    Blackstein M, Eisenhauer EA, Bramwell V, et al. Docetaxel (Taxotere) as first line therapy for metastatic or recurrent soft tissue sarcoma (STS): a Phase II Trial of the National Cancer Institute of Canada Clinical Trials Group [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S177CrossRefGoogle Scholar
  171. 171.
    Waltzman R, Schwartz GK, Shorter S, et al. Lack of efficacy of paclitaxel (Taxol) in patients with advanced soft tissue sarcoma (STS) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 526Google Scholar
  172. 172.
    Ajani JA, Ilson DH, Daugherty K, et al. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086–91PubMedCrossRefGoogle Scholar
  173. 173.
    Einzig AV, Lipsitz S, Wiernik PH, et al. Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). Invest New Drugs 1995; 13: 223–7PubMedCrossRefGoogle Scholar
  174. 174.
    Einzig AI, Lipsitz S, Wiernik PJ, et al. Phase II trial of Taxotere in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) previously untreated with cytotoxic chemotherapy; the Easter Cooperative Oncology Group (ECOG) results [abstract]. Proc Am Soc Clin Oncol 1995; 14: 191Google Scholar
  175. 175.
    Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere™) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994; 70: 380–3PubMedCrossRefGoogle Scholar
  176. 176.
    Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma or the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12: 2264–70PubMedGoogle Scholar
  177. 177.
    Dreicer R, Gustin D, See WA, et al. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy [abstract]. Proc Am Soc Clin Oncol 1996: 15: 242Google Scholar
  178. 178.
    McCaffrey J, Hilton S, Bajorin D, et al. Docetaxel in patients with advanced transitional cell cancer (TCC) who failed cisplatin based chemotherapy [abstract]. Proc Am Soc Clin Oncol 1995: 14: 233Google Scholar
  179. 179.
    Christou A, Roth B, Fox S, et al. Phase II trial of paclitaxel in refractory germ cell neoplasms [abstract]. Proc Am Soc Clin Oncol 1996; 15: 249Google Scholar
  180. 180.
    Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin refractory testicular cancer. Ann Oncol 1996; 7: 31–4PubMedCrossRefGoogle Scholar
  181. 181.
    Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277–83PubMedGoogle Scholar
  182. 182.
    Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995; 22: 67–75PubMedGoogle Scholar
  183. 183.
    Woo HL, Swenerton KD, Hoskins PJ. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol 1996; 19: 290–1PubMedCrossRefGoogle Scholar
  184. 184.
    Wilson WH, Chabner BA, Bryant G, et al. Phase II study of paclitaxel in relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1995; 13: 381–6PubMedGoogle Scholar
  185. 185.
    Younes A, Sarris A, Melnyk A, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1995; 13: 583–7PubMedGoogle Scholar
  186. 186.
    Younes A, Ayoub J-P, Hagemeister FB, et al. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin’s lymphoma refractory to a 3-hour schedule. J Clin Oncol 1996; 14: 543–8PubMedGoogle Scholar
  187. 187.
    Goss P, Stewart A, Couture F, et al. A phase II study of paclitaxel in patients with refractory lymphomas [abstract]. Proc Am Soc Clin Oncol 1996: 15: 419Google Scholar
  188. 188.
    Dimopoulos MA, Arbuck S, Huber M, et al. Primary therapy of multiple myeloma with paclitaxel (Taxol). Ann Oncol 1994; 5: 757–9PubMedGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.National Cancer Institute of Canada Clinical Trials GroupQueen’s UniversityKingstonCanada
  2. 2.University Hospital AntwerpEdegemBelgium

Personalised recommendations